title: More about the "ARB MI paradox".
abstract: "Logic dictates that angiotensin converting enzyme inhibitors should remain the preferred drug across the entire spectrum of cardiometabolic disease"
authors: Alistair S
authors: AS
authors: Hall
authors: Martin H
authors: MH
authors: Strauss
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D004334:Drug Administration Schedule; D006801:Humans; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents
references: N Engl J Med. 2003 Nov 13;349(20):1963-5
references: 14610159
references: N Engl J Med. 2003 Nov 13;349(20):1893-906
references: 14610160
references: Lancet. 2004 Jun 19;363(9426):2022-31
references: 15207952
references: Lancet. 2004 Jun 19;363(9426):2049-51
references: 15207957
references: Blood Press. 1998 May;7(3):176-83
references: 9758088
references: Circulation. 1999 Sep 7;100(10):1056-64
references: 10477530
references: J Hypertens. 2007 May;25(5):951-8
references: 17414657
references: Stroke. 2005 Jun;36(6):1218-26
references: 15879332
references: Hypertension. 2005 Aug;46(2):386-92
references: 16009786
references: J Hypertens. 2006 Aug;24(8):1679-81; author reply 1681-2
references: 16877973
references: Circulation. 2006 Aug 22;114(8):838-54
references: 16923768
references: Circulation. 2006 Aug 22;114(8):855-60
references: 16923769
references: J Hypertens. 2004 Dec;22(12):2265-6
references: 15614017